Last reviewed · How we verify

MK-8266 BID, 1.8 mg

Merck Sharp & Dohme LLC · Phase 1 active Small molecule Quality 15/100

MK-8266 BID, 1.8 mg is a Small molecule drug developed by Merck Sharp & Dohme LLC. It is currently in Phase 1 development. Also known as: MK-8266.

At a glance

Generic nameMK-8266 BID, 1.8 mg
Also known asMK-8266
SponsorMerck Sharp & Dohme LLC
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about MK-8266 BID, 1.8 mg

What is MK-8266 BID, 1.8 mg?

MK-8266 BID, 1.8 mg is a Small molecule drug developed by Merck Sharp & Dohme LLC.

Who makes MK-8266 BID, 1.8 mg?

MK-8266 BID, 1.8 mg is developed by Merck Sharp & Dohme LLC (see full Merck Sharp & Dohme LLC pipeline at /company/merck).

Is MK-8266 BID, 1.8 mg also known as anything else?

MK-8266 BID, 1.8 mg is also known as MK-8266.

What development phase is MK-8266 BID, 1.8 mg in?

MK-8266 BID, 1.8 mg is in Phase 1.

What are the side effects of MK-8266 BID, 1.8 mg?

Common side effects of MK-8266 BID, 1.8 mg include Headache, Supraventricular tachycardia, Ventricular tachycardia, Ear pain, Lacrimation increased, Application site pruritus.

Related